These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20636534)

  • 1. Relative safety of buffy coat platelet pools.
    Devine D; Jenkins C; Howe D; Goldman M
    Transfusion; 2010 Jul; 50(7):1591-2; author reply 1592-3. PubMed ID: 20636534
    [No Abstract]   [Full Text] [Related]  

  • 2. [Quality of thrombocyte preparations from buffy coat or platelet-rich plasma].
    Bux J; Müller K; Misterek J; Mueller-Eckhardt C
    Beitr Infusionsther; 1990; 26():99-102. PubMed ID: 1703912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ethics of wasting the donor's gift of buffy coat.
    Vamvakas EC
    Vox Sang; 2011 Feb; 100(2):256-7; author reply 258-9. PubMed ID: 20825600
    [No Abstract]   [Full Text] [Related]  

  • 4. Preparation, storage and quality control of platelet concentrates.
    Tynngård N
    Transfus Apher Sci; 2009 Oct; 41(2):97-104. PubMed ID: 19699153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two septic transfusion reactions presenting as transfusion-related acute lung injury from a split plateletpheresis unit.
    Rollins MD; Molofsky AB; Nambiar A; Pandey S; Weiskopf RB; Toy P
    Crit Care Med; 2012 Aug; 40(8):2488-91. PubMed ID: 22809916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet transfusion associated with acute lung injury after coronary artery bypass grafting.
    Fitzmaurice GJ; Parissis HD
    Ann Thorac Surg; 2011 Jun; 91(6):1977-9. PubMed ID: 21619998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating thrombocytopenia with pathogen-reduced platelets.
    Sandler SG
    Curr Hematol Rep; 2006 Mar; 5(1):53-4. PubMed ID: 16537046
    [No Abstract]   [Full Text] [Related]  

  • 8. A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States.
    Kleinman S; Grossman B; Kopko P
    Transfusion; 2010 Jun; 50(6):1312-21. PubMed ID: 20456690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical comparison of platelet preparation methods.
    Vassallo RR; Murphy S
    Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial contamination in platelet concentrates.
    Pietersz RN; Reesink HW; Panzer S; Oknaian S; Kuperman S; Gabriel C; Rapaille A; Lambermont M; Deneys V; Sondag D; Ramírez-Arcos S; Goldman M; Delage G; Bernier F; Germain M; Vuk T; Georgsen J; Morel P; Naegelen C; Bardiaux L; Cazenave JP; Dreier J; Vollmer T; Knabbe C; Seifried E; Hourfar K; Lin CK; Spreafico M; Raffaele L; Berzuini A; Prati D; Satake M; de Korte D; van der Meer PF; Kerkhoffs JL; Blanco L; Kjeldsen-Kragh J; Svard-Nilsson AM; McDonald CP; Symonds I; Moule R; Brailsford S; Yomtovian R; Jacobs MR
    Vox Sang; 2014 Apr; 106(3):256-83. PubMed ID: 24654780
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality and safety of platelet apheresis concentrates produced with a new leukocyte reduction system.
    Riggert J; Humpe A; Simson G; Köhler M
    Vox Sang; 1998; 74(3):182-8. PubMed ID: 9595646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments.
    Kleinman S; Dumont LJ; Tomasulo P; Bianco C; Katz L; Benjamin RJ; Gajic O; Brecher ME
    Transfusion; 2009 May; 49(5):903-12. PubMed ID: 19170988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preparation of leukocyte-reduced platelet concentrates from buffy coats using a novel separation apparatus].
    Müller N; Krüssel H
    Beitr Infusionsther Transfusionsmed; 1994; 32():52-4. PubMed ID: 9480156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
    Vasconcelos E; Figueiredo AC; Seghatchian J
    Transfus Apher Sci; 2003 Aug; 29(1):13-6. PubMed ID: 12877887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical aspects of treatment with platelet concentrates.
    Lanzer G
    Acta Anaesthesiol Scand Suppl; 1996; 109():141-3. PubMed ID: 8901986
    [No Abstract]   [Full Text] [Related]  

  • 16. Logistics of platelet concentrates.
    Vox Sang; 2007 Feb; 92(2):160-81. PubMed ID: 17298581
    [No Abstract]   [Full Text] [Related]  

  • 17. Do manual and automated processes with distinct additive solutions affect whole blood-derived platelet components differently?
    Nguyen KA; Chavarin P; Arthaud CA; Cognasse F; Garraud O
    Blood Transfus; 2013 Jan; 11(1):152-3. PubMed ID: 22871820
    [No Abstract]   [Full Text] [Related]  

  • 18. How much residual plasma may cause TRALI?
    Win N; Chapman CE; Bowles KM; Green A; Bradley S; Edmondson D; Wallis JP
    Transfus Med; 2008 Oct; 18(5):276-80. PubMed ID: 18937733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets.
    Schrezenmeier H; Walther-Wenke G; Müller TH; Weinauer F; Younis A; Holland-Letz T; Geis G; Asmus J; Bauerfeind U; Burkhart J; Deitenbeck R; Förstemann E; Gebauer W; Höchsmann B; Karakassopoulos A; Liebscher UM; Sänger W; Schmidt M; Schunter F; Sireis W; Seifried E
    Transfusion; 2007 Apr; 47(4):644-52. PubMed ID: 17381623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter on Bacterial contamination in platelet concentrates.
    Harm SK; Delaney M; Aubuchon JP; Triulzi DJ; Yazer MH
    Vox Sang; 2014 Oct; 107(3):312. PubMed ID: 25040131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.